Ligand Pharmaceuticals (LGND) Key Ratios
$289.50
As on 20-Nov-2026 12:39EST
Market cap
$6,177 Mln
Revenue (TTM)
$254 Mln
P/E Ratio
124
P/B Ratio
6.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 23.63 | -31.80 | 1.03 | 24.90 | -1.56 |
| EBIT | -164.06 | -129.19 | -12.91 | -17.79 | 5.03 |
| Net Profit | -158.72 | -124.29 | 5.93 | 46.16 | -5.51 |
| EPS | -164.24 | -125.10 | 7.91 | 38.89 | -10.87 |
| Book Value | -- | -- | 9.95 | 10.80 | 2.50 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 37.20 | 33.78 | 22.60 | 59.29 | 3.32 |
| Net Margin
| -- | 24.89 | 20.27 | -- | -- |
| Return on equity
| 6.99 | 4.75 | 5.25 | 13.47 | -0.53 |
| Return on Capital
| 5.92 | 3.81 | -- | 10.79 | -0.52 |
| Return on Assets
| 5.40 | 3.45 | 2.42 | 9.95 | -0.47 |
| Debt to Equity (x)
| -- | -- | 0.71 | 0.44 | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
--
|
10.79
|
-0.52
|
7.49
|
-3.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
5.25
Lower than Peers by 10.64
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
5.25
|
13.47
|
-0.53
|
8.03
|
-4.70
|
|
Peer Median
|
15.89
|
--
|
--
|
--
|
--
|
ROA
2.42
Lower than Peers by 0.26
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
2.42
|
9.95
|
-0.47
|
6.73
|
-3.24
|
|
Peer Median
|
2.69
|
--
|
--
|
--
|
--
|
EBIT Margin
22.60
Higher than Peers by 9.74
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
22.60
|
59.29
|
3.32
|
48.98
|
19.27
|
|
Peer Median
|
12.86
|
--
|
--
|
--
|
--
|
Net Margin
20.27
Higher than Peers by 12.80
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
20.27
|
46.42
|
-2.41
|
39.72
|
-17.00
|
|
Peer Median
|
7.47
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
1.03
Lower than Peers by 7.52
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
1.03
|
0.60
|
0.27
|
-0.33
|
-0.19
|
|
Peer Median
|
8.55
|
--
|
--
|
--
|
--
|
EBIT Growth
-12.91
Lower than Peers by 21.05
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
-12.91
|
2,761.57
|
-91.36
|
70.10
|
-58.82
|
|
Peer Median
|
8.14
|
--
|
--
|
--
|
--
|
Net Profit Growth
5.93
Lower than Peers by 0.68
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
5.93
|
3,186.63
|
-107.73
|
256.33
|
-158.39
|
|
Peer Median
|
6.61
|
--
|
--
|
--
|
--
|
EPS Growth
7.91
Lower than Peers by 0.94
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
7.91
|
28.71
|
-1.07
|
2.49
|
-1.58
|
|
Peer Median
|
8.85
|
--
|
--
|
--
|
--
|
Book Value Growth
4.60
Lower than Peers by 0.80
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
4.60
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.40
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.71
Higher than Peers by 0.27
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
0.71
|
0.44
|
0.01
|
0.01
|
0.15
|
|
Peer Median
|
0.44
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.47
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
0.47
|
0.00
|
0.00
|
0.00
|
0.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.22
Lower than Peers by 0.64
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
1.22
|
22.23
|
8.93
|
14.15
|
2.67
|
|
Peer Median
|
1.86
|
--
|
--
|
--
|
--
|
Quick Ratio
1.19
Lower than Peers by 0.15
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
1.19
|
21.98
|
8.55
|
12.72
|
2.53
|
|
Peer Median
|
1.34
|
--
|
--
|
--
|
--
|
Interest Coverage
7.45
Higher than Peers by 1.29
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
7.45
|
33.71
|
1.83
|
98.04
|
21.02
|
|
Peer Median
|
6.15
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
42.36
Higher than Peers by 21.07
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
42.36
|
22.77
|
25.40
|
29.94
|
17.85
|
|
Peer Median
|
21.29
|
--
|
--
|
--
|
--
|
Asset Turnover
0.12
Lower than Peers by 0.29
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
0.12
|
0.21
|
0.19
|
0.17
|
0.19
|
|
Peer Median
|
0.41
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
--
|
70.50
|
89.34
|
103.40
|
117.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
--
|
644.28
|
628.04
|
194.16
|
140.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
--
|
234.84
|
126.32
|
40.30
|
47.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
--
|
479.94
|
591.06
|
257.26
|
210.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
124.01
Higher than Peers by 69.17
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
124.01
|
32.11
|
-504.23
|
24.21
|
-33.82
|
|
Peer Median
|
54.84
|
--
|
--
|
--
|
--
|
Price / Book Value
6.58
Lower than Peers by 0.70
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
6.58
|
3.93
|
2.45
|
1.80
|
1.89
|
|
Peer Median
|
7.27
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
73.08
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
73.08
|
19.27
|
43.73
|
10.89
|
12.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
6,177
Higher than Peers by 4,651
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
6,177
|
--
|
--
|
--
|
--
|
|
Peer Median
|
1,525
|
--
|
--
|
--
|
--
|